Mechanisms underlying stress-induced hyperglycemia in critically ill patients

Therapy

Volumn 4, Issue 1, 2007, Pages 97-106

  Kajbaf, Farshad ^a   Mojtahedzadeh, Mojtaba ^a   Abdollahi, Mohammad ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Antihyperglycemic reagents; Critical illnesses; Hyperglycemia; Insulin resistance; Intensive insulin therapy

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; CYTOKINE; FATTY ACID; GELATINASE A; GELATINASE B; GLUCOSE; GLUCOSE TRANSPORTER 4; GROWTH FACTOR; HIGH DENSITY LIPOPROTEIN; HYDROCORTISONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; INSULIN RECEPTOR SUBSTRATE 1; INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 8; METFORMIN; MUSCLE PROTEIN; PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP); REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR AP 1; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ACUTE DISEASE; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; BLOOD CLOTTING; CRITICALLY ILL PATIENT; CYTOKINE RELEASE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DYSLIPIDEMIA; ENZYME ACTIVATION; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; GLYCOGENOLYSIS; HEART INFARCTION; HEART PROTECTION; HORMONE RELEASE; HUMAN; HYPERGLYCEMIA; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INHIBITION KINETICS; INSULIN RESISTANCE; INSULIN TREATMENT; LACTIC ACIDOSIS; MEDICAL LITERATURE; MEDLINE; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PROGNOSIS; PROTEIN TRANSPORT; REVIEW; SEPSIS; STRESS; SURGICAL PATIENT; SURVIVAL RATE; TRAUMATOLOGY;

EID: 33847269137     PISSN: 14750708     EISSN: 1744831X     Source Type: Journal    
DOI: 10.2217/14750708.4.1.97     Document Type: Review

References (98)

1. Mizock BA: Alterations in fuel metabolism in critical illness: hyperglycaemia. Best Pract. Res. Clin. Endocrinol. Metab. 15(4), 533-551 (2001).
2. Robinson LE, van Soeren MH: Insulin resistance and hyperglycemia in critical illness: role of insulin in glycemic control. AACN Clin. Iss. 15(1), 45-62 (2004).
3. van den Berghe G, Wouters P, Weekers F: Intensive insulin therapy in the critically ill patients. N. Engl. J. Med. 345(19), 1359-1367 (2001).
4. Krinsley JS: Effect of an intensive glucose management protocol on the mortality of critically ill adult patients. Mayo Clin. Proc. 79(8), 992-1000 (2004).
5. Van den Berghe G, Wilmer A, Hermans G et al.: Intensive insulin therapy in the medical ICU. N. Engl. J. Med. 354(5), 449-461 (2006).
6. Vanhorebeek I, Langouche L, Van den Berghe G: Glycemic and nonglycemic effects of insulin: how do they contribute to a better outcome of critical illness? Curr. Opin. Crit. Care 11(4), 304-311 (2005).
7. Pittas AG, Siegel RD, Lau J: Insulin therapy and in-hospital mortality in critically ill patients: systematic review and meta-analysis of randomized controlled trials. JPEN J. Parenter. Enteral. Nutr. 30(2), 164-172 (2006).
8. Lazar HL, Chipkin S. Philippides G, Bao, Y, Apstein C: Glucose-insulin-potassium solutions improve outcomes in diabetics who have coronary artery operations. Ann. Thorac. Surg. 70(1), 145-150 (2000).
9. Brown G, Dodek P: Intravenous insulin nomogram improves blood glucose control in the critically ill. Crit. Care Med. 29(9), 1714-1719 (2001).
10. Dilkhush D, Lannigan J, Pedroff T, Riddle A, Tittle M: Insulin infusion protocol for critical care units. Am. J. Health Syst. Pharm. 62(21), 2260-2264 (2005).
11. Pozzilli P, Leslie RD: Infections and diabetes: mechanisms and prospects for prevention. Diabet. Med. 11(10), 935-941 (1994).
12. Butler SO, Btaiche IF, Alaniz C: Relationship between hyperglycemia and infection in critically ill patients. Pharmacotheraphy 25(7), 963-976 (2005).
13. Turina M, Fry DE, Polk HC Jr: Acute hyperglycemia and the innate immune system: clinical, cellular, and molecular aspects. Crit. Care Med. 33(7), 1624-1633 (2005).
14. Gore DC, Chinkes D, Heggers J, Herndon DN, Wolf SE, Desai M: Association of hyperglycemia with increased mortality after severe burn injury. J. Trauma 51(3), 540-544 (2001).
15. Mowlavi A, Andrews K, Milner S, Herndon DN, Heggers JP: The effects of hyperglycemia on skin graft survival in the burn patient. Ann. Plast. Surg. 45(6), 629-632 (2000).
16. Furnary AP, Zerr KJ, Grunkemeier GL, Starr A: Continuous intravenous insulin infusion reduces the incidence of deep sternal wound infection in diabetic patients after cardiac surgical procedures. Ann. Thorac. Surg. 67(2), 352-360 (1999).
17. Capes SE, Hunt D, Malmberg K, Gerstein HC: Suess hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview. Lancet 355(9206), 773-778 (2000).
18. O'Neill PA, Davies I, Fullerton KJ, Bennett D: Stress hormone and blood glucose response following acute stroke in the elderly. Stroke 22(7), 842-847 (1991).
19. Norhammar AM, Ryden L, Malmberg K: Admission plasma glucose. Independent risk factor for long-term prognosis after myocardial infarction even in nondiabetic patients. Diabetes Care 22(11), 1827-1831 (1999).
20. Laird AM, Miller PR, Kilgo PD, Meredith JW, Chang MC: Relationship of early hyperglycemia to mortality in trauma patients. J. Trauma 56(5), 1058-1062 (2004).
21. Bochicchio GV, Sung J, Joshi M et al: Persistent hyperglycemia is predictive of outcome in critically ill trauma patients. J. Trauma 58(5), 921-924 (2005).
22. Beishuizen A, Thijs LG: The immunoneuroendocrine axis in critical illness: beneficial adaptation or neuroendocrine exhaustion? Curr. Opin. Crit. Care 10(6), 461-467 (2004).
23. Andreelli F, Jacquier D, Troy S: Molecular aspects of insulin therapy in critically ill patients. Curr. Opin. Clin. Nutr. Metab. Care 9(2), 124-130 (2006).
24. Rosmarin DK, Wardlaw GM, Mirtallo J: Hyperglycemia associated with high, continuous infusion rates of total parenteral nutrition dextrose. Nutr. Clin. Pract. 11(4), 151-156 (1996).
25. Mechanick JI: Metabolic mechanisms of stress hyperglycemia. J. Parenter. Enteral. Nutr. 30(2), 157-163 (2006).
26. Bateman A, Singh A, Kral T, Solomon S: The immune-hypothalamic-pituitary-adrenal axis. Endocr. Rev. 10(1), 92-112 (1989).
27. Blalock JE: Harnessing a neural immune circuit to control inflammation and shock. J. Exp. Med. 195(6), F25-F28 (2002).
28. Imura H, Fukata J: Endocrine-paracrine interaction in communication between the immune and endocrine systems. Activation of the hypothalamic-pituitary-adrenal axis in inflammation. Eur. J. Endocrinol. 130(1), 32-37 (1994).
29. Chrousos GP: The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N. Engl. J. Med. 332(20), 1351-1362 (1995).
30. Frayn KN: Hormonal control of metabolism in trauma and sepsis. Clin. Endocrinol. (Oxf.) 24(5), 577-599 (1986).
31. Miyoshi H, Shulman GI, Peters EJ, Wolfe MH, Elahi D, Wolfe RR: Hormonal control of substrate cycling in humans. J. Clin. Invest. 81(5), 1545-1555 (1988).
32. Uyama N, Geerts A, Reynaert H: Neural connections between the hypothalamus and the liver. Anat. Rec. A. Discov. Mol. Cell Evol. Biol. 280(1), 808-820 (2004).
33. Moore MC, Connolly CC, Cherrington AD: Autoregulation of hepatic glucose production. Eur. J. Endocrinol. 138(3), 240-248 (1998).
34. Khani S, Tayek JA: Cortisol increases gluconeogenesis in humans: its role in the metabolic syndrome. Clin. Sci. (Lond.) 101(6), 739-747 (2001).
35. Hanson RW, Reshef L: Regulation of phosphoenolpyruvate carboxykinase (GTP) gene expression. Annu. Rev. Biochem. 66, 581-611 (1997).
36. Vermes I, Beishuizen A: The hypothalamic-pituitary-adrenal response to critical illness. Best Pract. Res. Clin. Endocrinol. Metab. 15(4), 495-511 (2001).
37. Van den Berghe G, de Zegher F, Bouillon R: Clinical review 95: acute and prolonged critical illness as different neuroendocrine paradigms. J. Clin. Endocrinol. Metab. 83(6), 1827-1834 (1998).
38. Gustavson SM, Chu CA, Nishizawa M et al: Interaction of glucagon and epinephrine in the control of hepatic glucose production in the conscious dog. Am. J. Physiol. Endocrinol. Metab. 284(4), E695-E707 (2003).
39. Hunt DG, Ivy JL: Epinephrine inhibits insulin-stimulated muscle glucose transport. J. Appl. Physiol. 93(5), 1638-1643 (2002).
40. Itani SI, Ruderman NB, Schmieder F, Boden G: Lipid-induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C, and IκB-α. Diabetes 51(7), 2005-2011 (2002).
41. Gearhart MM, Parbhoo SK: Hyperglycemia in the critically ill patient. AACN Clin. Iss. 17(1), 50-55 (2006).
42. Lang CH: Sepsis-induced insulin resistance in rats is mediated by a β-adrenergic mechanism. Am. J. Physiol. 263(4 Pt 1), E703-E711 (1992).
43. Smith TR, Elmendorf JS, David TS, Turinsky J: Growth hormone-induced insulin resistance: role of the insulin receptor, IRS-1, GLUT-1, and GLUT-4. Am. J. Physiol 272(6 Pt 1), E1071-E1079 (1997).
44. Payen D, Faivre V, Lukaszewicz AC, Losser MR: Assessment of immunological status in the critically ill. Minerva Anestesiol. 66(5), 351-357 (2000).
45. Menger MD, Vollmar B: Surgical trauma: hyperinflammation versus immunosuppression? Langenbecks Arch. Surg. 389(6), 475-484 (2004).
46. Hotamisligil GS: Inflammatory pathways and insulin action. Int. J. Obes. Relat. Metab. Disord. 27(Suppl. 3), S53-S55 (2003).
47. Kanety H, Feinstein R, Papa MZ, Hemi R, Karasik A: Tumor necrosis factor α-induced phosphorylation of insulin receptor substrate-1 (IRS-1). Possible mechanism for suppression of insulin-stimulated tyrosine phosphorylation of IRS-1. J. Biol. Chem. 270(40), 23780-23784 (1995).
48. Paz K, Hemi R, LeRoith D et al.: A molecular basis for insulin resistance. Elevated serine/threonine phosphorylation of IRS-1 and IRS-2 inhibits their binding to the juxtamembrane region of the insulin receptor and impairs their ability to undergo insulin-induced tyrosine phosphorylation. J. Biol. Chem. 272(47), 29911-29918 (1997).
49. Marik PE, Raghavan M: Stress-hyperglycemia, insulin and Immunomodulation in sepsis. Intensive Care Med. 30(5), 748-756 (2004).
50. Barnes PJ, Karin M: Nuclear factor-κB: a pivotal transcription factor in chronic inflammatory diseases. N. Engl. J. Med. 336(15), 1066-1071 (1997).
51. Flores EA, Istfan N, Pomposelli JJ, Blackburn GL, Bistrian BR: Effect of interleukin-1 and tumor necrosis factor/cachectin on glucose turnover in the rat. Metabolism 39(7), 738-743 (1990).
52. Mastorakos G, Chrousos GP, Weber JS: Recombinant interleukin-6 activates the hypothalamic-pituitary-adrenal axis in humans. J. Clin. Endocrinol. Metab. 77(6), 1690-1694 (1993).
53. Devin A, Lin Y, Yamaoka S, Li Z, Karin M, Liu Zg: The α and β subunits of IκB kinase (IKK) mediate TRAF2-dependent IKK recruitment to tumor necrosis factor (TNF) receptor 1 in response to TNF. Mol. Cell Biol. 21(12), 3986-3994 (2001).
54. Hadidi E, Mojtahedzadeh M, Paknejad MH et al: Alterations of blood IL-8, TGF-β1 and nitric oxide levels in relation to blood cells in patients with acute brain injury. Therapy 3(3), 399-405 (2006).
55. Mohanty P, Hamouda W, Garg R, Aljada A, Ghanim H, Dandona P: Glucose challenge stimulates reactive oxygen species (ROS) generation by leucocytes. J. Clin. Endocrinol. Metab. 85(8), 2970-2973 (2000).
56. Astaneie F, Afshari M, Mojtahedi A et al.: Total antioxidant capacity and levels of epidermal growth factor and nitric oxide in blood and saliva of insulin-dependent diabetic patients. Arch. Med. Res. 36(4), 376-381 (2005).
57. Rahimi R, Nikfar S, Larijani B, Abdollahi M: A review on the role of antioxidants in the management of diabetes and its complications. Biomed. Pharmacother. 59(7), 365-373 (2005).
58. Guha M, Bai W, Nadler JL, Natarajan R: Molecular mechanisms of tumor necrosis factor α gene expression in monocytic cells via hyperglycemia-induced oxidant stress-dependent and -independent pathways. J. Biol. Chem. 275(23), 17728-17739 (2000).
59. Aljada A, Ghanim H, Mohanty P, Syed T, Bandyopadhyay A, Dandona P: Glucose intake induces an increase in activator protein 1 and early growth response 1 binding activities, in the expression of tissue factor and matrix metalloproteinase in mononuclear cells, and in plasma tissue factor and matrix metalloproteinase concentrations. Am. J. Clin. Nutr. 80(1), 51-57 (2004).
60. Esposito K, Nappo F, Marfella R et al.: Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation 106(16), 2067-2072 (2002).
61. Morohoshi M, Fujisawa K, Uchimura I, Numano F: The effect of glucose and advanced glycosylation end products on IL-6 production by human monocytes. Ann. NY Acad. Sci. 748, 562-570 (1995).
62. Yu WK, Li WQ, Li N, Li JS: Influence of acute hyperglycemia in human sepsis on inflammatory cytokine and counterregulatory hormone concentrations. World J. Gastroenterol. 9(8), 1824-1827 (2003).
63. Dandona P, Mohanty P, Chaudhuri A, Garg R, Aljada A: Insulin infusion in acute illness. J. Clin. Invest. 115(8), 2069-2072 (2005).
64. Weekers F, Giulietti AP, Michalaki M et al.: Metabolic, endocrine, and immune effects of stress hyperglycemia in a rabbit model of prolonged critical illness. Endocrinology 144(12), 5329-5338 (2003).
65. Nielson CP, Hindson DA: Inhibition of polymorphonuclear leukocyte respiratory burst by elevated glucose concentrations in vitro. Diabetes 38(8), 1031-1035 (1989).
66. Savage DB, Petersen KF, Shulman GI: Mechanisms of insulin resistance in humans and possible links with inflammation. Hypertension 45(5), 828-833 (2005).
67. Sheetz MJ, King GL: Molecular understanding of hyperglycemia's adverse effects for diabetic complications. JAMA 288(20), 2579-2588 (2002).
68. Klip A, Tsakiridis T, Marette A, Ortiz PA: Regulation of expression of glucose transporters by glucose: a review of studies in vivo and in cell cultures. FASEB J. 8(1), 43-53 (1994).
69. Thong FS, Dugani CB, Klip A: Turning signals on and off. GLUT4 traffic in the insulin-signaling highway. Physiology (Bethesda) 20, 271-284 (2005).
70. Kono T, Nishida M, Nishiki Y, Seki Y, Sato K, Akiba Y: Characterisation of glucose transporter (GLUT) gene expression in broiler chickens. Br. Poult. Sci. 46(4), 510-515 (2005).
71. Shikhman AR, Brinson DC, Valbracht J, Lotz MK: Cytokine regulation of facilitated glucose transport in human articular chondrocytes. J. Immunol. 167(12), 7001-7008 (2001).
72. Quinn LA, McCumbee WD: Regulation of glucose transport by angiotensin II and glucose in cultured vascular smooth muscle cells. J. Cell Physiol. 177(1), 94-102 (1998).
73. Sanchez-Alvarez R, Tabernero A, Medina JM: Endothelin-1 stimulates the translocation and upregulation of both glucose transporter and hexokinase in astrocytes: relationship with gap junctional communication. J. Neurochem. 89(3), 703-714 (2004).
74. Clerici C, Matthay MA: Hypoxia regulates gene expression of alveolar epithelial transport proteins. J. Appl. Physiol. 88(5), 1890-1896 (2000).
75. Vanhorebeek I, De Vos R, Mesotten D, Wouters PJ, De Wolf-Peeters C, Van den Berghe G: Protection of hepatocyte mitochondrial ultrastructure and function by strict blood glucose control with insulin in critically ill patients. Lancet 365(9453), 53-59 (2005).
76. West IC: Radicals and oxidative stress in Diabetes Diabet. Med. 17(3), 171-180 (2000).
77. Brealey D, Brand M, Hargreaves I et al.: Association between mitochondrial dysfunction and severity and outcome of septic shock. Lancet 360(9328), 219-223 (2002).
78. Dandona P, Aljada, A, Mohanty P et al.: Insulin inhibits intranuclear nuclear factor κB and stimulates IκB in mononuclear cells in obese subjects: evidence for an anti-inflammatory effect? J. Clin. Endocrinol. Metab. 86(7), 3257-3265 (2001).
79. Aljada A, Ghanim H, Mohanty P, Kapur N, Dandona P: Insulin inhibits the pro-inflammatory transcription factor early growth response gene-1 (Egr)-1 expression in mononuclear cells (MNC) and reduces plasma tissue factor (TF) and plasminogen activator inhibitor-1 (PAI-1) concentrations. J. Clin. Endocrinol. Metab. 87(3), 1419-1422 (2002).
80. Hansen TK, Thiel S, Wouters PJ, Christiansen JS, Van den Berghe G: Intensive insulin therapy exerts antiinflammatory effects in critically ill patients and counteracts the adverse effect of low mannose-binding lectin levels. J. Clin. Endocrinol. Metab. 88(3), 1082-1088 (2003).
81. Landin K, Tengborn L, Chmielewska J, von Schenck H, Smith U: The acute effect of Insulin on tissue plasminogen activator and plasminogen activator inhibitor in man. Thromb. Haemost. 65(2), 130-133 (1991).
82. Fendri S, Roussel B, Lormeau B, Tribout B, Lalau JD: Insulin sensitivity, insulin action, and fibrinolysis activity in nondiabetic and diabetic obese subjects. Metabolism 47(11), 1372-1375 (1998).
83. Langouche L, Vanhorebeek I, Vlasseiaers D et al.: Intensive insulin therapy protects the endothelium of critically ill patients. J. Clin. Invest. 115(8), 2277-2286 (2005).
84. Gao F, Gao E, Yue TL et al.: Nitric oxide mediates the antiapoptotic effect of insulin in myocardial ischemia-reperfusion: the roles of PI3-kinase, Akt, and endothelial nitric oxide synthase phosphorylation. Cirulation 105(12), 1497-1502 (2002).
85. Das UN: Insulin: an endogenous cardioprotector. Curr. Opin. Crit. Care 9(5), 375-383 (2003).
86. Mesotten D, Swinnen JV, Vanderhoydonc F, Wouters PJ, Van den Berghe G: Contribution of circulating lipids to the improved outcome of critical illness by glycemic control with intensive insulin Therapy J. Clin. Endocrinol. Metab. 89(1), 219-226 (2004).
87. Jabbar MA, Zuhri-Yafi MI, Larrea J: Insulin therapy for a non-diabetic patient with severe hypertriglyceridemia. J. Am. Coll. Nutr. 17(5), 458-461 (1998).
88. Finney SJ, Zekveld C, Elia A, Evans TW: Glucose control and mortality in critically ill patients. JAMA 290(15), 2041-2047 (2003).
89. Ghanim H, Garg R, Aljada A et al.: Suppression of nuclear factor-κB and stimulation of inhibitor κB by troglitazone: evidence for an anti-inflammatory effect and a potential antiatherosclerotic effect in the obese. J. Clin. Endocrinol. Metab. 86(3), 1306-1312 (2001).
90. Isoda K, Young JL, Zirlik A et al.: Metformin inhibits proinflammatory responses and nuclear factor-κB in human vascular wall cells. Arterioscler. Thromb. Vasc. Biol. 26(3), 611-617 (2006).
91. Gore DC, Wolf SE, Herndon DN, Wolfe RR: Metformin blunts stress-induced hyperglycemia after thermal injury. J. Trauma 54(3), 555-561 (2003).
92. Gore DC, Herndon DN, Wolfe RR: Comparison of peripheral metabolic effects of insulin and metformin following severe burn injury. J. Trauma 59(2), 316-322 (2005).
93. Kirpichnikov D, McFarlane SI, Sowers JR: Metformin: an update. Ann. Intern. Med. 137(1), 25-33 (2002).
94. Zhou G, Myers R, Li Y et al.: Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest. 108(8), 1167-1174 (2001).
95. Musi N, Goodyear LJ: AMP-activated protein kinase and muscle glucose uptake. Acta Physiol. Scand. 178(4), 337-345 (2003).
96. Hardie DG: Minireview: the AMP-activated protein kinase cascade: the key sensor of cellular energy status. Endocrinology 144(12), 5179-5183 (2003).
97. Stades AM, Heikens JT, Erkelens DW, Holleman F, Hoekstra JB: Metformin and lactic acidosis: cause or coincidence? A review of case reports. J. Intern. Med. 255(2), 179-187 (2004).
98. Salpeter SR, Greyber E. Pasternak GA, Salpeter EE: Risk of fatal and nonfatal lactic acidosis with metformin use in Type 2 diabetes mellitus: systematic review and meta-analysis. Arch. Intern. Med. 163(21), 2594-2602 (2003).